AHL Partners’s TherapeuticsMD TXMD Stock Holding History

AHL Partners’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-234	Closed	-$62K	–	1373
2017 Q3	$62K	Buy	+234	New	+$67.7K	﹤0.01%	1221
2016 Q4	–	Sell	-919	Closed	-$313K	–	1184
2016 Q3	$313K	Buy	+919	New	+$336K	0.01%	972

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AHL Partners's TXMD Position: Q4 2017 in Review

AHL Partners sold out of TherapeuticsMD (TXMD) in Q4 2017, closing a stake of 234 shares — an estimated $62K sold.

AHL Partners first reported a position in TXMD in Q3 2016 and held it in 2 quarters. The position peaked at $313K in Q3 2016. 144 funds tracked by Wall St. Rank hold TXMD as of Q4 2017.

AHL Partners reported no remaining TherapeuticsMD position as of Q4 2017 after selling out during the quarter.
AHL Partners sold 234 TherapeuticsMD shares in Q4 2017, an estimated $62K.
AHL Partners first reported a position in TherapeuticsMD in Q3 2016 and held it in 2 quarters.
AHL Partners's TherapeuticsMD position peaked at $313K in Q3 2016.
144 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.